Claims
- 1. A method for treatment of viral infections in animals including man, comprising administering to an animal so infected a compound of the formula ##STR88## wherein R.sub.1 is selected from the group consisting of hydrogen, alkyl containing 1-6 carbon atoms, cycloalkyl containing 3-6 carbon atoms, cycloalkyl-alkyl containing 4-6 carbon atoms, 1-adamantyl, 2-adamantyl and benzyl; R.sub.2 is hydrogen and R.sub.3 is selected from the group containing hydrogen and benzyl, provided that when R.sub.3 is H, then R.sub.1 is alkyl, cycloalkyl or cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl or benzyl, or a physiologically acceptable salt or an optical isomer thereof in an amount sufficient for treating said viral infections.
- 2. A method according to claim 7, wherein the virus is selected from the group consisting of herpes virus, influenza virus and hepatitis B virus.
- 3. A method for the treatment of viral infections in animals including man, by inhibiting the activity of viral polymerase, comprising administering to an animal so infected a compound of the formula ##STR89## wherein R.sub.1 is selected from the group consisting of hydrogen, alkyl containing 1-6 carbon atoms, cycloalkyl containing 3-6 carbon atoms, cycloalkyl-alkyl containing 4-6 carbon atoms, 1-adamantyl, 2-adamantyl and benzyl; R.sub.2 is hydrogen and R.sub.3 is selected from the group containing hydrogen and benzyl, provided that when R.sub.3 is H, then R.sub.1 is alkyl, cycloalkyl or cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl or benzyl, or a physiologically acceptable salt or an optical isomer thereof in an amount sufficient for inhibiting the activity of said viral polymerase.
- 4. A method for inhibiting the activity of viral reverse transcriptase in animals including man, comprising administering to an animal in need of such treatment a compound of the formula ##STR90## wherein R.sub.1 is selected from the group consisting of hydrogen, alkyl containing 1-6 carbon atoms, cycloalkyl containing 3-6 carbon atoms, cycloalkyl-alkyl containing 4-6 carbon atoms, 1-adamantyl, 2-adamantyl and benzyl; R.sub.2 is hydrogen and R.sub.3 is selected from the group containing hydrogen and benzyl, provided that when R.sub.3 is H, then R.sub.1 is alkyl, cycloalkyl or cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl or benzyl, or a physiologically acceptable salt or an optical isomer thereof in an amount sufficient for inhibiting the activity of said reverse transcriptase.
- 5. A method for inhibiting the growth of virus-transformed cells in animals including man, comprising administering to an animal in need of such treatment a compound of the formula ##STR91## wherein R.sub.1 is selected from the group consisting of hydrogen, alkyl containing 1-6 carbon atoms, cycloalkyl containing 3-6 carbon atoms, cycloalkyl-alkyl containing 4-6 carbon atoms, 1-adamantyl-2-adamantyl and benzyl; R.sub.2 is hydrogen and R.sub.3 is selected from the group containing hydrogen and benzyl, provided that when R.sub.3 is H, then R.sub.1 is alkyl, cycloalkyl or cycloalkyl-alkyl as defined above, or 1-adamantyl-2-adamantyl or benzyl, or a physiologically acceptable salt or an optical isomer thereof in an amount sufficient for inhibiting said growth.
- 6. A method as in any of claims 1, 3, 4 or 5 wherein, in the compound of the formula I, the radicals R.sub.1 and R.sub.2 are hydrogen and R.sub.3 is benzyl.
- 7. A method as in any of claims 1, 3, 4 or 5 wherein the compound is in the form of its sodium salt.
Priority Claims (8)
Number |
Date |
Country |
Kind |
53580/77 |
Dec 1977 |
GBX |
|
53581/77 |
Dec 1977 |
GBX |
|
53582/77 |
Dec 1977 |
GBX |
|
53583/77 |
Dec 1977 |
GBX |
|
28548/78 |
Jul 1978 |
GBX |
|
28552/78 |
Jul 1978 |
GBX |
|
28553/78 |
Jul 1978 |
GBX |
|
28555/78 |
Jul 1978 |
GBX |
|
Parent Case Info
This application is a divisional of Application Ser. No. 093,167, filed on Nov. 13, 1979, now U.S. Pat. No. 4,386,081, which is a continuation-in-part of application Ser. No. 971,896, filed on Dec. 21, 1978, now abandoned.
Foreign Referenced Citations (1)
Number |
Date |
Country |
2238432 |
Mar 1980 |
FRX |
Non-Patent Literature Citations (5)
Entry |
Alenius, et al., "Therapeutic Effect of Trisodium Phosphonoformate on Cutaneus Herpes Virus Infection in Guinea Pigs," Antimicrobial Agents and Chemotherapy, Sep. 1978. |
Palmer, et al., "Disodium Phosphonoacetate in Cream Base as a Possible Topical Treatment for Skin Lesions at Herpes Simplex Virus in Cebus Monkeys," Antimicrobial Agents and Chemotherapy, Oct. 1977. |
Chemical Abstracts, vol. 50, No. 2, 794d, (1956). |
Galasso, "An Assessment of Antiviral Drugs for the Management of Infectious Diseases in Humans," Antiviral Research, 1 (1981), 73-96. |
Kern et al., "Treatment of Experimental Herpesvirus Infections with Phosphonoformate and Some Comparisons with Phosphonoacetate", Antimicrobial Agents and Chemotherapy, 14 (Dec. 1978), 817-823. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
93167 |
Nov 1979 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
971896 |
Dec 1978 |
|